BTAI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioXcel Therapeutics Inc (BTAI) is not a good buy for a beginner investor with a long-term strategy at this time. The stock shows bearish technical indicators, poor financial performance, and lacks positive catalysts or strong trading signals. The absence of recent news, significant insider or hedge fund activity, and congress trading data further diminishes its appeal.
The technical indicators are bearish. The MACD histogram is negative and contracting, RSI is neutral at 42.203, and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.543, with key resistance at 1.681 and support at 1.405.
No positive catalysts identified. No recent news or significant insider/hedge fund activity.
Revenue dropped by -54.21% YoY in Q3 2025, EPS fell by -57.67% YoY, and gross margin dropped significantly by -119.87% YoY. The stock also lacks any recent congress trading data or influential figure activity.
In Q3 2025, the company reported a significant revenue drop (-54.21% YoY) and a decrease in EPS (-57.67% YoY). Although net income improved by 126.45% YoY, it remains negative at -30.91M. Gross margin also declined sharply to 88.78, down -119.87% YoY.
No recent analyst ratings or price target changes available for review.
